Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection

2018 ◽  
Vol 17 (5) ◽  
pp. 450-455 ◽  
Author(s):  
Nam Hee Kim ◽  
Hong Joo Kim
Keyword(s):  
Risk Factors ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Surgical Resection ◽  
Early Recurrence ◽  
Ductal Adenocarcinoma ◽  
Preoperative Risk ◽  
Curative Intent ◽  
Preoperative Risk Factors

scholarly journals Pancreatic ductal adenocarcinoma from a surgical perspective

2021 ◽  
Vol 6 (2) ◽  
Keyword(s):  
Risk Factors ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Adjuvant Treatment ◽  
Locally Advanced ◽  
Historical Background ◽  
Ductal Adenocarcinoma ◽  
Curative Intent ◽  
Pancreatic Cancers ◽  
Operative Care ◽  
Histological Staging

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of pancreatic cancers. Whilst most patients present with locally advanced or metastatic disease, a minority are candidates for curative-intent resection. This review covers the aspects of PDAC which are relevant to the surgeon. Firstly, an up-to-date overview of epidemiology, risk factors and pathogenesis are provided. Secondly, presentation, diagnosis and staging are covered, including a summary of the most recent staging guidelines. The review will then focus on the historical background of the pancreatico-duodenectomy (PD), the modern procedure and post-operative care. Finally, short sections provide the reader with an update on histological staging and adjuvant treatment.

Prevalence of radiologic evidence of metastatic pancreatic ductal adenocarcinoma (PDAC) at first post-operative restaging studies in patients (pts) undergoing pancreatic cancer surgery with curative intent.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 225-225
Author(s):  
Sofia Palacio ◽  
Peter Joel Hosein ◽  
Joe U Levi ◽  
Jaime R. Merchan ◽  
Jorge Monge ◽  
...  
Keyword(s):  
Ct Scan ◽  
Disease Progression ◽  
Surgical Resection ◽  
Metastatic Disease ◽  
Disease Recurrence ◽  
Early Recurrence ◽  
Ductal Adenocarcinoma ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Curative Intent

225 Background: Surgical resection is the only potentially curative modality for PDAC. However, even after a successful surgical resection outcomes are poor due to both local and distant disease recurrence. Patients with early recurrence likely derive no benefit from surgery and could be considered for a non-surgical approach as initial therapy. Since the incidence of recurrent/metastatic disease at first post-operative staging scan is not well documented, our aim was to determine this incidence. Methods: This IRB-approved analysis identified all pts diagnosed with resectable PDAC that underwent surgery with intent to cure at the University of Miami/Sylvester Comprehensive Cancer Center between 2010 and 2012. Patients with imaging before and within 6 months after surgery were included. All post-operative CT scans performed within 3 months after surgery were reviewed for the presence of recurrent and/or metastatic disease. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Results: Data from105 pts were analyzed. Mean age was 61, 63% were male, 91% had adenocarcinoma, 84% had disease in the head of the pancreas. 11 out of 85 (13%) pts had recurrent/metastatic disease detected on first post-operative CT scan; 64% stage IIB and 73% had positive lymph nodes. 54 out of 105 (51%) had disease progression. 60% had local recurrence, 40% had distant metastasis. The mean time from preoperative CT scan to surgery was 35 days. Patients with early and late recurrence had similar OS from diagnosis (median 27.7 and 27.1 months, respectively) but worse than those with no disease recurrence (median not reached, OS rate 78% at 36 months). Conclusions: The relatively high incidence (13%) of early recurrence in this retrospective cohort suggests that further studies aimed at improving patient selection for surgery are warranted and provides a strong rationale for the use of neoadjuvant therapy to select patients with early disease progression who would not have benefitted from surgery.

scholarly journals Early recurrence of hepatocellular carcinoma after curative intent surgical resection – Risk factors & Recurrence patterns.

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S358
Author(s):  
Santhosh Kumar Ganapathi ◽  
Chandrasekar Murugesan ◽  
Kunal Sadanand Joshi ◽  
Sisir Bodepudi ◽  
Jagan Balu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Surgical Resection ◽  
Early Recurrence ◽  
Curative Intent ◽  
Recurrence Patterns

scholarly journals Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma

2019 ◽  
Vol 54 (1) ◽  
pp. 95-100 ◽  
Author(s):  
Dingyuan Hu ◽  
Daniel Ansari ◽  
Qimin Zhou ◽  
Agata Sasor ◽  
Katarzyna Said Hilmersson ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Surgical Resection ◽  
Early Recurrence ◽  
Ductal Adenocarcinoma

scholarly journals Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yejong Park ◽  
Hye Ryeong Jun ◽  
Hwi Wan Choi ◽  
Dae Wook Hwang ◽  
Jae Hoon Lee ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Surgical Resection ◽  
Distant Metastases ◽  
Early Recurrence ◽  
Tumour Cells ◽  
Ductal Adenocarcinoma ◽  
Circulating Tumour Cells ◽  
Active Monitoring ◽  
Systemic Recurrence ◽  
Recurrence Patterns

AbstractEarly recurrence in pancreatic ductal adenocarcinoma (PDAC) is a decisive factor in determining a patient's prognosis. We determined in our current study whether circulating tumour cells (CTCs) exist in the blood of PDAC patients and can be used as a predictor of recurrence patterns (i.e. time and site) after surgical resection. Between December 2017 and November 2018, the mononuclear cell layer was obtained from the peripheral blood of 36 patients diagnosed with PDAC. CTCs were then isolated using the CD-PRIME™ platform and detected via immunostaining. The patient records were analyzed to correlate these data with survival and recurrence patterns. Twelve patients were CTC-positive (33.3%) and showed a significantly frequent rate of systemic recurrence (distant metastases and peritoneal dissemination) (p = 0.025). On multi-variable logistic regression analysis, CTC positivity was an independent risk factor for early recurrence (p = 0.027) and for systemic recurrence (p = 0.033). In summary, the presence or absence of CTC in the blood of the patients with PDAC could help predict the recurrence pattern after surgery. PDAC patients with CTC positivity at tumour diagnosis should therefore undergo a comprehensive strategy for systemic therapy and active monitoring to detect possible early recurrence.

Sign in / Sign up

Export Citation Format

Share Document